Fmr LLC lifted its holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 0.2% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,874,780 shares of the biopharmaceutical company’s stock after buying an additional 36,006 shares during the period. Fmr LLC owned approximately 14.99% of Lexicon Pharmaceuticals worth $190,497,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in LXRX. LPL Financial LLC lifted its stake in Lexicon Pharmaceuticals by 34.1% in the first quarter. LPL Financial LLC now owns 29,172 shares of the biopharmaceutical company’s stock valued at $250,000 after purchasing an additional 7,426 shares during the last quarter. Price Capital Management Inc. purchased a new position in Lexicon Pharmaceuticals in the second quarter valued at approximately $1,352,000. UBS Group AG lifted its stake in Lexicon Pharmaceuticals by 94.5% in the first quarter. UBS Group AG now owns 218,923 shares of the biopharmaceutical company’s stock valued at $1,876,000 after purchasing an additional 106,392 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its stake in Lexicon Pharmaceuticals by 6.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 241,061 shares of the biopharmaceutical company’s stock valued at $2,893,000 after purchasing an additional 14,426 shares during the last quarter. Finally, Sector Gamma AS lifted its stake in Lexicon Pharmaceuticals by 0.9% in the second quarter. Sector Gamma AS now owns 862,602 shares of the biopharmaceutical company’s stock valued at $10,351,000 after purchasing an additional 8,010 shares during the last quarter.
Several equities analysts recently commented on the company. Zacks Investment Research upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 3rd. Needham & Company LLC reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Monday, July 30th. BidaskClub upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, August 30th. ValuEngine downgraded Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 17th. Finally, Citigroup dropped their price objective on Lexicon Pharmaceuticals from $27.00 to $26.00 and set a “buy” rating on the stock in a research note on Friday. Two analysts have rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $25.25.
Lexicon Pharmaceuticals stock opened at $8.49 on Friday. Lexicon Pharmaceuticals, Inc. has a 12 month low of $7.42 and a 12 month high of $13.97. The company has a current ratio of 2.71, a quick ratio of 2.68 and a debt-to-equity ratio of 8.85. The company has a market capitalization of $898.91 million, a P/E ratio of -6.69 and a beta of 0.73.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.07. The firm had revenue of $6.90 million for the quarter, compared to the consensus estimate of $12.56 million. Lexicon Pharmaceuticals had a negative return on equity of 560.01% and a negative net margin of 168.23%. The business’s quarterly revenue was down 74.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.29) earnings per share. On average, analysts predict that Lexicon Pharmaceuticals, Inc. will post -1.38 earnings per share for the current year.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Further Reading: Moving Average (MA)
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.